{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T01:17:35Z","timestamp":1782868655309,"version":"3.54.5"},"reference-count":34,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019717","name":"AstraZeneca Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019717","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clinthera.2026.03.016","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T11:40:14Z","timestamp":1776512414000},"page":"495-502","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tezepelumab in the Framework of Use in Special Situations Before Commercialization: T-ROSS, a Retrospective Real-world Study in Spain"],"prefix":"10.1016","volume":"48","author":[{"given":"Ismael","family":"Garc\u00eda Moguel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Ramos-Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Alegr\u00eda Llorente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Niza Fresno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Robles Ma\u00f1ueco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Monteagudo Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Velasco Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2026.03.016_bib0001","unstructured":"Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Updated 2021. Accessed November 2025, https:\/\/ginasthma.org\/wp-content\/uploads\/2021\/05\/GINA-Main-Report-2021-V2-WMS.pdf."},{"key":"10.1016\/j.clinthera.2026.03.016_bib0002","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2147\/JAA.S404525","article-title":"The ATLAS ASMA Study: assessing the impact of asthma on patients\u2019 life\u2014the Spanish patients\u2019 perspective","volume":"16","author":"Dominguez-Ortega","year":"2023","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.clinthera.2026.03.016_bib0003","unstructured":"Gu\u00eda Espa\u00f1ola para el Manejo del Asma (GEMA) versi\u00f3n 5.5. Comit\u00e9 Ejecutivo GEMA SEPAR. Accessed May 2025.https:\/\/www.separ.es\/gema-5.5-asma."},{"key":"10.1016\/j.clinthera.2026.03.016_bib0004","doi-asserted-by":"crossref","first-page":"97","DOI":"10.18176\/jiaci.0871","article-title":"Prevalence, T2 biomarkers, and cost of severe asthma in the era of biologics: the BRAVO-1 Study","volume":"34","author":"Domingo","year":"2024","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.clinthera.2026.03.016_bib0005","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.03.016_bib0006","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.clinthera.2026.03.016_bib0007","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S2213-2600(21)00226-5","article-title":"Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"9","author":"Diver","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.clinthera.2026.03.016_bib0008","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","article-title":"Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE","volume":"60","author":"Humbert","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.clinthera.2026.03.016_bib0009","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s12931-020-01505-x","article-title":"Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option?","volume":"21","author":"Menzies-Gow","year":"2020","journal-title":"Respir Res"},{"key":"10.1016\/j.clinthera.2026.03.016_bib0010","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.03.016_bib0011","article-title":"Tezepelumab reduces multiple key inflammatory biomarkers in patients with severe, uncontrolled asthma in the phase 2b PATHWAY study","volume":"199","author":"Pham","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clinthera.2026.03.016_bib0012","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0221-2024","article-title":"The epithelial era of asthma research: knowledge gaps and future direction for patient care","volume":"33","author":"Brightling","year":"2024","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.clinthera.2026.03.016_bib0013","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa1402895","article-title":"Effects of an anti-TSLP antibody on allergen-induced asthmatic responses","volume":"370","author":"Gauvreau","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.03.016_bib0014","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.03.016_bib0015","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1111\/all.15197","article-title":"Baseline type 2 biomarker levels and response to tezepelumab in severe asthma","volume":"77","author":"Corren","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.clinthera.2026.03.016_bib0016","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.03.016_bib0017","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300135","article-title":"Tezepelumab and mucus plugs in patients with moderate-to-severe asthma","volume":"2","author":"Nordenmark","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.clinthera.2026.03.016_bib0018","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/all.15918","article-title":"Tezepelumab decreases airway epithelial IL-33 and T2-inflammation in response to viral stimulation in patients with asthma","volume":"79","author":"Sverrild","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.clinthera.2026.03.016_bib0019","article-title":"The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM)","volume":"59","author":"Sverrild","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.clinthera.2026.03.016_bib0020","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Acceso a medicamentos en situaciones especiales. Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). https:\/\/www.aemps.gob.es\/medicamentos-de-uso-humano\/acceso-a-medicamentos-en-situaciones-especiales\/. Accessed March 4, 2026."},{"key":"10.1016\/j.clinthera.2026.03.016_bib0021","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.jaip.2024.05.052","article-title":"Real-world data on tezepelumab in patients with severe asthma in Germany","volume":"12","author":"Biener","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.clinthera.2026.03.016_bib0022","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaip.2025.09.001","article-title":"Tezepelumab in real-life practice: characteristics of patients commenced and efficacy in a nationwide, Danish cohort of patients with severe asthma","volume":"14","author":"Soendergaard","year":"2026","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.clinthera.2026.03.016_bib0023","doi-asserted-by":"crossref","DOI":"10.23822\/EurAnnACI.1764-1489.416","article-title":"Real-life efficacy of tezepelumab in patients with failure to other biologic drugs","author":"Miralles-L\u00f3pez","year":"2025","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2026.03.016_bib0024","doi-asserted-by":"crossref","first-page":"193","DOI":"10.15586\/aei.v53i5.1448","article-title":"Efficacy of tezepelumab in patients with severe allergic asthma in clinical practice","volume":"53","author":"Miralles-L\u00f3pez","year":"2025","journal-title":"Allergol Immunopathol (Madr)"},{"key":"10.1016\/j.clinthera.2026.03.016_bib0025","doi-asserted-by":"crossref","first-page":"163","DOI":"10.15586\/aei.v53i2.1326","article-title":"Real-life effectiveness of tezepelumab in severe asthma","volume":"53","author":"Miralles-L\u00f3pez","year":"2025","journal-title":"Allergol Immunopathol (Madr)"},{"key":"10.1016\/j.clinthera.2026.03.016_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115185","article-title":"Short-term therapeutic effectiveness of tezepelumab in patients with severe asthma: a real-world study","volume":"162","author":"Pelaia","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.clinthera.2026.03.016_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejim.2025.106528","article-title":"Effectiveness of tezepelumab in severe asthma: a multicenter real-world study","volume":"143","author":"Poto","year":"2026","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.clinthera.2026.03.016_bib0028","doi-asserted-by":"crossref","first-page":"00314","DOI":"10.1183\/23120541.00314-2025","article-title":"Real-world evidence of tezepelumab for severe asthma: a retrospective multicentre cohort","volume":"11","author":"Khateeb","year":"2025","journal-title":"ERJ Open Res"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2026.03.016_bib0029","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.jaci.2025.04.037","article-title":"A critical look at the lexicon, parameters, and limitations of asthma remission definitions","volume":"156","author":"Jackson","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2026.03.016_bib0030","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.jaci.2025.05.033","article-title":"Consensus summary on the definition of asthma remission","volume":"156","author":"Katial","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2026.03.016_bib0031","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0181-2024","article-title":"Pro: clinical remission in asthma\u2014implications for asthma management","volume":"34","author":"Principe","year":"2025","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.clinthera.2026.03.016_bib0032","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1111\/all.16590","article-title":"Clinical and biological remission with tezepelumab: the real-world response in severe uncontrolled asthma","volume":"80","author":"Gates","year":"2025","journal-title":"Allergy"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2026.03.016_bib0033","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.jaci.2025.05.034","article-title":"Current data on biologics: evaluating clinical remission in asthma","volume":"156","author":"Pavord","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2026.03.016_bib0034","doi-asserted-by":"crossref","first-page":"4724","DOI":"10.1007\/s12325-025-03316-2","article-title":"Correction to: Effectiveness and safety of tezepelumab in a diverse population of US patients with severe asthma: initial results of the PASSAGE study","volume":"42","author":"Lugogo","year":"2025","journal-title":"Adv Ther"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826000780?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826000780?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T13:35:10Z","timestamp":1779284110000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291826000780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0149291826000780"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.03.016","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tezepelumab in the Framework of Use in Special Situations Before Commercialization: T-ROSS, a Retrospective Real-world Study in Spain","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}